Science

Clinical review: Psilocybin therapy could be significantly better than current psychiatric treatments

December 11, 2017By 0 comment

Thomas and his two colleagues, Benjamin Malcolm and Dan Lastra, came to this conclusion after reviewing seven clinical trials on psilocybin-assisted therapy. These previous studies were published over the past decade and examined cancer-related anxiety, obsessive-compulsive disorder, depressive disorders, and addiction. “This therapy has also demonstrated large effect sizes for improving symptoms on validated psychiatric…

READ MORE
Science

Is Kratom the CBD of opioids?

December 5, 2017By 0 comment

*Peace Monument in Washington D.C. Could Kratom be the CBD of the opiate world? … Ironically, the greatest danger of Kratom these days is from fake products contaminated with substances approved by the FDA. In rats, there was no observed toxicity following single, huge oral doses up to 806 mg/kg of [mitragyine]. (CBD is also…

READ MORE

National expert: no cases show deaths solely from coffee-like herb kratom, which should be handled no differently than other substances

November 30, 2017By 0 comment

“…kratom… has not been linked to any known deaths, and the plant has little potential for abuse and dependence – as low or lower than such widely used (and federally unscheduled substances) as “nutmeg, hops, St. John’s Wort, chamomile, guarana, and kola nut.” -Dr. Henningfield* Dr. Henningfield previously served as chief of the Clinical Pharmacology…

READ MORE
Science

Posttreatment brain effects of psilocybin in patients with treatment-resistant depression

November 28, 2017By 0 comment

Changes in resting-state brain blood flow and functional connectivity following the use of psilocybin in patients with treatment-resistant depression have been documented for the first time, according to the results of a recent open-label UK study published in Scientific Reports. Investigators collected functional magnetic resonance imaging (fMRI) data from patients with treatment-resistant depression in order…

READ MORE
Science

Kratom LD-50 Stats

November 21, 2017By 0 comment

[It appears], you’d need to eat a whole tree in one sitting to die of kratom. Both alkaloid extract (ED50=194.4 mg/kg) and mitragynine (ED50= 21.96 mg/kg) significantly and dose-dependently showed analgesic effect compared to morphine (ED50=3.69 mg/kg). In addition, based on the acute toxicity study the LD50 for alkaloid extract and mitragynine was estimated 591.6…

READ MORE
Science

Mom opens up about alcohol addiction

November 17, 2017By 0 comment

GRAPH : How each substance performs regarding the average (dashed line) of overall weighted scores. Substances above the dashed line (red) do more harm than the average value. Substances below the dashed line (pale pink) do less harm than average value. The shocking reality of the role alcohol plays in people’s lives has been revealed in a…

READ MORE
Science

What LSD tells us about human nature

November 3, 2017By 0 comment

Healthy volunteers were injected with LSD while lying in an MRI scanner, and subjected to several other neuroimaging methods at the same time. This amounted to an arsenal of measurement that previous decades of psychedelic researchers could only dream of. ​Humans have gathered, cultivated, distilled, and manufactured all kinds of drugs for thousands of years.…

READ MORE

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms

October 13, 2017By 0 comment

This study was approved by the National Research Ethics Service (NRES) committee London – West London and was conducted in accordance with the revised declaration of Helsinki (2000), the International Committee on Harmonisation Good Clinical Practice (GCP) guidelines and National Health Service (NHS) Research Governance Framework. Imperial College London sponsored the research which was conducted…

READ MORE
Science

Mind-altering therapy : psilocybin therapy to combat depression

October 4, 2017By 0 comment

Spokesperson Tracey Cheung told us natural psilocybin extraction is difficult and expensive to produce to cGMP standards. “Given the urgent unmet need, Compass has chosen to synthesize psilocybin to expedite research and regulatory approval to bring this treatment to patients without unecessary delays,” she said. “We plan to extend research into extracts at a later…

READ MORE